Exact Sciences announced the results of its DeeP-C clinical study comparing the efficacy of Cologuard, a multi-target stool DNA-based screening test, to the fecal immunochemical test.
The study found:
• Cologuard detected 92 percent of colorectal cancer, compared to 74 percent in FIT
• Cologuard detected 93 percent of colorectal cancers in Stages I-III, while FIT detected 73 percent
• Cologuard demonstrated a 42 percent sensitivity level in patients with advanced precancerous lesions, while FIT demonstrated 24 percent sensitivity
• Cologuard detected 69 percent of patients with high-grade dysplasia polyps, while FIT detected 46 percent
• Cologuard had a specificity of 87 percent, while FIT had specificity of 95 percent
The results of the study were published in the New England Journal of Medicine.
More Articles on Gastroenterology:
ACG Partners With National Colorectal Cancer Roundtable to Works Toward '80 by 2018' Goal
28 Statistics on Colonoscopy Indications
10-Year Stretta Outcomes for GERD Treatment: Q&A With Dr. Mark Noar
The study found:
• Cologuard detected 92 percent of colorectal cancer, compared to 74 percent in FIT
• Cologuard detected 93 percent of colorectal cancers in Stages I-III, while FIT detected 73 percent
• Cologuard demonstrated a 42 percent sensitivity level in patients with advanced precancerous lesions, while FIT demonstrated 24 percent sensitivity
• Cologuard detected 69 percent of patients with high-grade dysplasia polyps, while FIT detected 46 percent
• Cologuard had a specificity of 87 percent, while FIT had specificity of 95 percent
The results of the study were published in the New England Journal of Medicine.
More Articles on Gastroenterology:
ACG Partners With National Colorectal Cancer Roundtable to Works Toward '80 by 2018' Goal
28 Statistics on Colonoscopy Indications
10-Year Stretta Outcomes for GERD Treatment: Q&A With Dr. Mark Noar